Pembrolizumab versus the standard of care for relapsed and refractory classical Hodgkin’s lymphoma progressing after brentuximab vedotin: an indirect treatment comparison
Year: 2018
Type: article
Source: Expert Review of Hematology
Authors: Sam Keeping, Elise Wu, Keith Chan, Ali Mojebi, Shannon Allen Ferrante, Arun Balakumaran
Institution: Merck & Co., Inc., Rahway, NJ, USA (United States)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Merck Sharp and Dohme
OpenAlex ID: W2804430290